Logistic regression analysis showed that only AHI was a predictor of daytime hypercapnia ... daytime hypercapnia may be directly linked to sleep apnea in a subgroup of patients with OSAS.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” Dr. Sally Seymour ...

The US Food and Drug Administration has approved the first ever prescribed medicine for Obstructive Sleep Apnea. Read on to find out more information.

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

The trials' main goal was improvement on a metric known as the apnea-hypopnea index, or AHI, the number of breathing disruptions during an hour of sleep. In both studies, the mean AHI to start was ...

The main measure of effectiveness was the change in the apnea hypopnea index (AHI), which tracks how often a person stops or has shallow breaths during sleep. After 52 weeks of treatment ...

To be included in the trial, patients had to have an apnea-hypopnea index (AHI) of at least 15 events ... Zepbound compared with placebo. Regarding sleep-related impairment, greater improvement ...